NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) COO Douglas F. Kling Sells 47,569 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) COO Douglas F. Kling sold 47,569 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $21.44, for a total value of $1,019,879.36. Following the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at $943,360. This trade represents a 51.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

NewAmsterdam Pharma Price Performance

NAMS stock traded up $0.22 during midday trading on Monday, hitting $22.42. The stock had a trading volume of 390,761 shares, compared to its average volume of 745,554. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -11.87 and a beta of -0.03. The business has a 50-day moving average of $19.35 and a two-hundred day moving average of $20.14. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. Research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in the stock. Avanza Fonder AB boosted its holdings in NewAmsterdam Pharma by 21.0% in the second quarter. Avanza Fonder AB now owns 7,505 shares of the company's stock worth $136,000 after acquiring an additional 1,300 shares in the last quarter. Atle Fund Management AB boosted its holdings in NewAmsterdam Pharma by 45.9% in the second quarter. Atle Fund Management AB now owns 157,223 shares of the company's stock worth $2,847,000 after acquiring an additional 49,440 shares in the last quarter. PTM Wealth Management LLC bought a new stake in NewAmsterdam Pharma in the second quarter worth $256,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in NewAmsterdam Pharma by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company's stock worth $5,898,000 after acquiring an additional 34,563 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in NewAmsterdam Pharma by 0.5% in the first quarter. Woodline Partners LP now owns 2,442,397 shares of the company's stock worth $49,996,000 after acquiring an additional 11,615 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on NAMS. Citigroup began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They set a "buy" rating and a $42.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Stifel Nicolaus began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They set a "buy" rating and a $44.00 target price on the stock. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They set an "overweight" rating and a $42.00 target price on the stock. Finally, The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research note on Thursday. They set a "neutral" rating and a $27.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $41.30.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.